150
Participants
Start Date
February 28, 2002
Primary Completion Date
September 30, 2003
Study Completion Date
September 30, 2003
PB127 for injectable suspension
0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
Mount Sinai Hospital, New York
University of Pittsburgh Cardiovascular Institute, Pittsburgh
Washington Hospital Center Cardiovascular Research Institute, Washington D.C.
University of Virginia Health System, Charlottesville
MidWest Cardiologist Research, Columbus
The Cleveland Clinic Foundation, Cleveland
Krannert Institute of Cardiology, Indianapolis
University of Chicago Medical Center, Chicago
St. Louis University Medical Center, St Louis
Washington University School of Medicine, St Louis
Cardiovascular Consultants, Kansas City
The Center for Cardiovascular Studies Kramer and Crouse Cardiology, Shawnee Mission
Dallas VA Medical Center, Dallas
Presbyterian Hospital of Dallas, Dallas
Methodist DeBakery Heart Center Cardiovascular Imaging Institute, Houston
University of Texas Health Sciences Center at San Antonio, San Antonio
Austin Heart, Austin
Michael Morgan, MD, Phoenix
Heartcare, P.C., Scottsdale
Mayo Clinic Scottsdale, Scottsdale
Long Beach VA Medical Center Cardiology Division, Long Beach
University of California San Diego Division of Cardiology, San Diego
San Francisco VA Medical Center NCIRE, San Francisco
University of California San Francisco, San Francisco
Stanford University Medical Center, Stanford
Oregon Health Sciences University, Portland
Endovascular Research, LLC, Eugene
Virginia Mason Medical Center, Seattle
Harborview Medical Center Department of Cardiology, Seattle
Inland Cardiology, Spokane
Northwest Cardiovascular Research Institute Spokane Cardiology, Spokane
Androscoggin Cardiovascular Associates, Auburn
Maine Cardiology Associates, South Portland
New England Medical Center, Boston
Lead Sponsor
Point Biomedical
INDUSTRY